A chartered accountant and his scientist partner are to earn £30m after
selling their company to bio-tech company, ML Laboratories.
The two, Rajan Uppal and Terrence Chadwick, bought Quadrant Technologies in
2003 and own a 64% controlling stake in the private company.
It has developed a method of stabilising drugs so they can be administered to
asthmatics via their inhalers, the technique understood to have prompted the
£46m offer from ML.
Uppal, 42, specialises in corporate finance and is understood to be the
business brains behind Quadrant. Chadwick, a former physician who develops new
formulations for drugs, is the creative force.
The two have accepted the offer from ML, which is likely to use Quadrant as a
basis of rebuilding its loss making business.
The average cost of fraud increased 35.4% to £3.9m in 2016, compared to 2015 data
Tallat Mahmood appointed to corporate finance team of Top 20 firm
Andrew Tyrie airs views on the Finance Bill, 'Making Tax Policy Better' report, and Brexit
Senior partner David Elliott has been appointed in KPMG’s Newcastle office